Episurf Medical announces re-structuring initiatives and increased focus towards the US market

Episurf Medical (Nasdaq: EPIS B) today announces that the company is initiating re-structuring initiatives to significantly reduce its operating expenses while still positioning itself for further growth. The initiatives are expected to lead to annual cost savings of SEK 20 million.

The company will significantly reduce operating expenses by reducing headcount, primarily impacting operations and sales in the European business. Episurf continues reorganising its sales organisation in Europe to handle sales through distributors, allowing a cost-effective business organisation that still can provide a high service level, although with a smaller internal organisation. The cost reductions are expected to have full effect as of the third quarter of 2025. The commercialisation in the US of the Episealer® Patellofemoral System will continue with full force, and the company looks forward to successfully completing the 510(k) process for market clearance for the big toe implant Episealer® MTP. Commercialisation remains the company’s highest priority. In the US, the customer group is growing by more than 100% YTD, which is in line with the company’s mid-term targets. The Episealer® Patellofemoral System represents a USD 300 million market opportunity in the US, and the company will increase its focus on further expanding the customer base and productivity. In Europe, the distribution co-operation with Joint Operations has started and Episurf is fully dedicated to educating Joint Operations’ sales force.

Based on the increased confidence in the US market in general, and in the company’s regulatory pipeline, Episurf will intensify its work regarding international partnering opportunities through dedicated external advisors.

“A direct, dedicated sales force was crucial to introduce the new technology in the market. With clinical acceptance in Europe, we have become a highly attractive supplier to distributors within joint preservation. With this initiative, the European business model will be similar to the one we established in the US. We are also making changes in other areas and continue to adapt the organisation. I want to sincerely thank the colleagues who are leaving Episurf as part of this reorganisation,” says Pål Ryfors, CEO, Episurf Medical.

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20.10 CEST on 2 July 2025.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Läs mer på Cision